openPR Logo
Press release

Shigella Vaccines Market Trends, Opportunities, Drivers with Top Players MSD Wellcome Trust Hilleman Laboratories, Novartis,GlaxoSmithKline

06-21-2019 09:45 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Shigella vaccines

Shigella vaccines

Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are encompassed, such as S. dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that are the polysaccharides moiety of the lipopolysaccharide, a virulence factor consist of toxic lipid. According to the Centers for Disease Control and Prevention (CDC), in 2013, the average annual incidence of shigellosis in the U.S. was around 5 cases per 100,000 individuals. Bacillary dysentery with brutal epidemics are caused by S. dysenteriae by the production of shiga toxins whereas, the endemic form of disease is caused by the S. flexneri and S. sonnei. The bacillary dysentery is accompanied with fever, rectal inflammation, and abdominal cramps.

According to World Health Organization (WHO), nearly one million people die from Shigella infection annually. Moreover, the high incidence rate is seen among children less than five years age, travelers, and military personnel from industrialized economies. Shigella species have been identified from centuries and it represents a major threat to public health, due to non-availability of licensed vaccine and thus affecting overall Shigella vaccines market.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1110

Developing vaccine against Shigella infections is difficult, due to the diversity of Shigella species and their serotypes. Shigella genome is continuously modified by deletion and acquisition of genes mediated by the mobile genetic elements, such as plasmids, insertion sequences, and integrons. These modifications are the major foundation for the generation of novel antibiotic resistant strains and it also leads to the formation of novel Shigella serotype variants. Centers for Disease Control and Prevention (CDC) in April 2017, warned the physicians and public health officials in the U.S. by stating that the recent strains of Shigella bacteria shows the reduced susceptibility to ciprofloxacin, which is one of the main antibiotics recommended by WHO for the treatment of shigellosis.

Geographically, S. flexneri is the most frequent species occurred worldwide accounting for most cases in emerging economies. Whereas, the S. sonnei is prevalent in Brazil, China, Vietnam, and Bangladesh, due to rapid industrialization of these economies. The primary prevention of Shigella is based on the universal provision of portable sanitation and water methods along with personal and food hygiene. However, a low cost and effective vaccine would accelerate disease reduction across the globe.

Joint ventures and collaborations of major players to develop and commercializes the vaccine are expected to propel the Shigella vaccines market in near future

Joint ventures and partnership of the players to develop and commercialize Shigella vaccine is expected to provide momentum to the Shigella vaccines market. For instance, in March 2017, Hilleman Laboratories, a non-profit organization established with joint venture partnership between Merck & Co., and Wellcome Trust has entered into an agreement with National Institute of Cholera and Enteric Disease (NICED) for the development and commercialization of vaccines against Shigella by 2024. Besides, in June 2016, Immuron- an Australian biopharmaceutical company entered into an agreement to produce Shigella vaccine with the U.S Army’s biomedical research lab-Walter Reed Army Institute of Research (WRAIR).

Prokarium and Probiomed in January 2017, collaborated to manufacture orally-administrated vaccine to prevent diarrhea. The new vaccine is expected to be manufactured as a part of two-year collaboration having thermostable capabilities for a longer period. The new vaccine is expected to be delivered to the people living in the remote areas. Thermostable vaccine, which is manufactured approximately one third of the price of the conventional injectable vaccines helps to facilities the growth of Shigella vaccines market.

The new research trial drives the Shigella vaccines market

The University Of Maryland School Of Medicine (UM SOM) in August 2017 received US$ 2.47 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop vaccine against Shigella and Enterotoxigenic Escherichia coli (ETEC) for the treatment of diarrheal disease. The researchers in the UM SOM’s Center for Vaccine Development (CVD) have developed Shigella-ETEC prototype vaccine, which has been tested in animals successfully. Moreover, the latest funding helps to translate prototype to a human vaccine for Phase 1 clinical trials.

The key players present in the global shigella vaccines market include MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc.

Get PDF Brochure of This Business Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1110

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Shigella Vaccines Market Trends, Opportunities, Drivers with Top Players MSD Wellcome Trust Hilleman Laboratories, Novartis,GlaxoSmithKline here

News-ID: 1783766 • Views: 359

More Releases from Coherent Market Insights

Advanced Metering Infrastructure Market Investment Activity From Established Com …
𝗥𝗲𝗽𝗼𝗿𝘁 𝗦𝘂𝗺𝗺𝗮𝗿𝘆: Coherent Market Insight has published a new research study "Global Advanced Metering Infrastructure Market Size, Share, Price, Trends, Growth, Report and Forecast 2022-2027" provides a complete '130 Pages' analysis of the global Advanced Metering Infrastructure Market market. The Global Advanced Metering Infrastructure Market research report employs primary and secondary research methodologies to provide users with a thorough picture of market trends. Analysts employed SWOT analysis and Porter's five forces
Advanced Metering Infrastructure Market Investment Activity From Established Com …
𝗥𝗲𝗽𝗼𝗿𝘁 𝗦𝘂𝗺𝗺𝗮𝗿𝘆: Coherent Market Insight has published a new research study "Global Advanced Metering Infrastructure Market Size, Share, Price, Trends, Growth, Report and Forecast 2022-2027" provides a complete '130 Pages' analysis of the global Advanced Metering Infrastructure Market market. The Global Advanced Metering Infrastructure Market research report employs primary and secondary research methodologies to provide users with a thorough picture of market trends. Analysts employed SWOT analysis and Porter's five forces
Swarm Intelligence Market Current Growth Factors, Which Will Affect the Competit …
𝗥𝗲𝗽𝗼𝗿𝘁 𝗦𝘂𝗺𝗺𝗮𝗿𝘆: Coherent Market Insight has published a new research study "Global Swarm Intelligence Market Size, Share, Price, Trends, Growth, Report and Forecast 2022-2027" provides a complete '130 Pages' analysis of the global Swarm Intelligence Market market. The Global Swarm Intelligence Market research report employs primary and secondary research methodologies to provide users with a thorough picture of market trends. Analysts employed SWOT analysis and Porter's five forces analysis to provide
Recycled Plastic Granules Market Growth and Share, Development Review, Regional …
The CMI's latest study report sheds light on changing dynamics of each of the segments and subsegments of the "Recycled Plastic Granules Market" and examines the investment in the market from 2022-2028. The research report contains all of the relevant facts. It provides market insight by providing accurate data to its clients, allowing them to make critical decisions. It provides an overview of the Recycled Plastic Granules market, including its

All 5 Releases


More Releases for Shigella

Shigella Vaccines Market Huge Growth in Future Scope 2021-2028 | Cochlear Limite …
The Shigella Vaccines Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this Shigella Vaccines Market report is to supply an in-depth view and strategic analysis of the parent industry. The report examines each segment also as their respective sub-segments present within the market in an all-inclusive manner. The report provides a deep
Shigella Vaccines Market 2020 To See Worldwide Massive Growth | Outlook, Trends, …
Coherent Market Insights added the most up-to-date research on “Shigella Vaccines Market” to its huge collection of research reports. The research analysis is a superb account of macroeconomic and microeconomic factors influencing the growth of the global Shigella Vaccines Market. This will help market players to make suitable changes in their approach towards attaining growth and maintaining their position in the industry. The global Shigella Vaccines Market is segmented as
Shigella Infection (Shigellosis) Therapeutics- Pipeline Analysis 2018
Shigella infection, also known as shigellosis, is a bacterial infection caused by a family of bacteria known as shigella. The main symptom of this infection is diarrhea, and can be passed through direct contact with the bacteria in the stool. Download the sample report @ https://www.pharmaproff.com/request-sample/1072 The other sign and symptoms associated with shigella infection are abdominal pain, cramps, and fever. Children between the age of two and four years are
The New Research Trial Drives The Shigella Vaccines Market
Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are encompassed, such as S. dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that are the polysaccharides moiety of the lipopolysaccharide, a virulence
Shigella Infections - Pipeline Analysis with Ongoing Trends in Therapeutic Devel …
Market Research Hubs’ Shigella Infections-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Shigella Infections. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Shigella Infections by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature
Research Report: Global Shigella Infections (Shigellosis) Market
MarketResearchReports.Biz presents this most up-to-date research on "Shigella Infections (Shigellosis)-API Insights, 2017" The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. View Complete